result in the failure of calmodulinopathy-affected LTCCs to inactivate during the plateau of the cardiac action potential (AP) and is predicted to prolong the AP duration (APD), a cellular correlate of prolonged QT intervals identified on the ECG. 10, 11 There are 3 distinct CaM genes, CALM1 (chr14q31), CALM2 (chr2p21), and CALM3 (chr19q13), with 85% nucleotide sequence homology that encode for completely identical 149 amino acid CaM proteins. In all reported cases of LQTS-associated calmodulinopathies, the mutation occurs heterozygously in one of these 3 redundant CALM genes, that is, with only 1 out of 6 alleles harboring the mutation. Thus, only a small fraction of mutant CaM protein causes the severe phenotype. This large dominant negative effect may be rationalized by the known preassociation of Ca 2+ -free CaM to the LTCCs. 10, 12 In fact, the reduction of CDI because of mutant CaM expression corresponds to a highly nonlinear effect such that a relatively small amount of mutant CaM can significantly decrease CDI in HEK293 cells. 10 However, this phenomenon remains to be substantiated in a cardiac system under conditions mimicking that of a calmodulinopathy patient. To this end, we generated induced pluripotent stem cells (iPSCs) from a patient harboring a heterozygous p.D130G-CaM mutation, 1 resulting from a single nucleotide substitution (c.389 A>G) within the CALM2 gene. Cardiomyocytes (CMs) differentiated from these cells (iPSC-CMs) offer an ideal platform for exploring the dominant negative effect of mutant CaM within a patient-specific genetic background and provide a model system with which to understand the pathogenesis and treatment options of CaM-mediated LQTS.
The nonlinear CDI effect in calmodulinopathies may also provide an opportunity for novel therapeutic interventions. Impaired repolarization resulting from a deficit of LTCC CDI exhibits a nonlinear threshold such that the fraction of channels harboring a CDI deficit can increase without overt electric dysfunction up to a critical threshold. At this point, addition of even a minute fraction of affected channels generates the substrate for flagrant arrhythmogenesis. 8 Should this threshold behavior hold true, a relatively small decrease in mutant CaM could result in a significant increase in electric stability and thus lead to substantial clinical improvement. To this end, we exploit the precise genetic control of a variant of CRISPR/ Cas9 technology, CRISPR interference (CRISPRi), [13] [14] [15] to selectively downregulate mutant CaM expression without permanently altering the genome. Taking advantage of the fact that patients with calmodulinopathies harbor mutations in only 1 of 3 CALM genes, mutant CaM could be attenuated while largely sparing wild-type (WT) CaM. As a test bed for therapeutic development, we use our D130G-CaM-containing iPSC-CMs (iPSC D130G-CaM -CMs) because these cells are able to form a functional syncytium with the genetic background of the patient. Such a disease model readily permits application of CRISPRi to downregulate mutant CALM genes and enables analysis of the functional effects of such a manipulation.
In this study, we demonstrate that iPSC-CMs derived from a patient harboring the p.D130G-CaM missense mutation within CALM2 accurately recapitulate the cellular LQTS phenotype. Specifically, the iPSC D130G-CaM -CMs demonstrate prolonged APs, disrupted Ca 2+ cycling, and diminished LTCC CDI, consistently across extended culture time. Having established a viable model system, we next use CRISPRi to selectively silence the expression of the CALM2 gene (both mutant and WT CALM2 alleles) and correlate this reduction with a functional rescue of the iPSC D130G-CaM -CMs. In particular, we have corrected fully the magnitude of CDI in these cells, resulting in normalization of the AP profile and therapeutic attenuation of the APD.
Methods

Study Participant
A p.D130G-CaM missense mutation secondary to c.389 A>G-CALM2 was identified previously in a young female patient with severe LQTS that was referred to the Windland Smith Rice Sudden Death Genomics Laboratory (M.J.A.) at Mayo Clinic, Rochester, MN, for research-based genetic testing. 1 This study was approved by the Mayo Foundation Institutional Review Board, and informed consent was obtained.
Generation of iPSCs
Dermal fibroblasts were isolated from a punch skin biopsy obtained from the p.D130G-CaM-positive patient and expanded in DMEM containing 10% fetal bovine serum. These fibroblasts were reprogrammed using the CytoTune-iPS 2.0 Sendai Reprogramming Kit (Invitrogen) according to manufacturer's recommendations. Colonies were isolated as separate clones and characterized for pluripotency based on immunofluorescent staining (Online Figures I and II) . Sanger sequencing of genomic DNA of each clone confirmed a heterozygous mutation c.389 A>G-CALM2. WT iPSCs used for control experiments were a generous gift from Dr Bruce Conklin. 16 All cell lines were tested negative for mycoplasma.
Cell Culture
IPSCs were cultured and differentiated in a feeder-free and xeno-free system using a modified protocol described previously. 17 Briefly, iPSCs were cultured on Geltrex matrix (Gibco)-coated tissue culture plates and fed daily with Essential 8 medium (Gibco). When cells were ≈30% confluent, they were mechanically dissociated using 0.5 mmol/L EDTA in Dulbecco's phosphate-buffered saline. For differentiation into cardiomyocytes, cells were dissociated and plated on fresh Geltrex matrix-coated plates. When confluent (day 0), media was exchanged with RPMI-1640 (Roswell Park Memorial Institute; Sigma-Aldrich) supplemented with B-27(-insulin) (Gibco) and 6 µmol/L CHIR99021. Cells were maintained in this media for the first 7 days, with medium exchange every 2 days. On day 3, 5 µmol/L 
CRISPRi Construction, Transfection, and Transduction
The lentiviral transfer vectors containing cDNA for enzymatically dead Cas9 fused with suppressor Krüppel-associated box (KRAB) and blue florescence protein (BFP; pHR-SFFV-dCas9-BFP-KRAB) was purchased from Addgene (plasmid #46911). BFP was replaced with monomeric ruby red fluorescence protein (mRuby). The entire construct (dCas9-mRuby-KRAB) was then cloned via Gibson assembly (New England Biolabs) into the lentiviral vector pRRLsin18.cPPT.CMV.eGFP.Wpre54. 18 The lentiviral vector (pKLVU6gRNA(BbsI)-PGKpuro2ABFP) containing cDNA for the guide RNA (gRNA) backbone (driven by the human U6 promoter) and a BFP marker (driven by PGK promoter) was purchased from Addgene (plasmid #50946), and BFP was replaced with cyan fluorescence protein. E-CRISPR gRNA sequence prediction program 19 was used to generate candidate gRNA sequences that selectively complement to the human CALM2 gene (Online Table I ). The candidate gRNA sequences were then cloned into the aforementioned lentiviral transfer vector using Golden Gate assembly.
For gRNA screening, both dCas9-mRuby-KRAB and candidate gRNA were expressed in HEK293 cells by transfection with polyethylenimine. 10 For iPSC-CM transduction, lentivirus was generated using Lenti-X-Concentrator (Clontech) according to the manufacturer's recommendations and added to monolayers on day 21 post differentiation. Expression was confirmed by mRuby and cyan fluorescence protein visualization.
MRNA Expression
Total RNA was extracted 4 days post transfection in HEK293 cells and 8 to 9 days post transduction in iPSC-CMs using an RNeasy Kit (Qiagen). Complementary DNA was made using the high-capacity cDNA reverse transcription kit (Applied Biosystems). Quantification of CALM mRNA levels was performed using quantitative real-time polymerase chain reaction with TaqMan gene expression assay (Applied Biosystems). CALM expression level was normalized to the expression level of a house-keeping gene GAPDH. Probe numbers are as follows: CALM1, Hs00300085_s1; CALM2, Hs00830212_s1; CALM3, Hs00968732_g1; and GAPDH, Hs02758991_g1.
Electrophysiology
Whole-cell recordings of iPSC-CMs were performed 28 to 30 days post differentiation at room temperature using an Axopatch 200B amplifier (Axon Instruments). Traces were low-pass filtered at 2 kHz and digitally sampled at 10 kHz. P/8 leak subtraction was used, ( 1) where r 50/Ba and r 50/Ca are currents remaining after 50 ms with Ba 2+ -and Ca
2+
-containing external solution.
Imaging
Monolayers of iPSC-CMs expressing either a genetically encoded voltage or Ca 2+ sensor (ASAP1 20 or GCaMP6f 21 , respectively, via lentiviral transduction) were paced using a custom field stimulation apparatus in RPMI-1640 medium with B-27 supplement. Expression efficiency of the genetically encoded sensors was assessed via flow cytometry (Online Figure III) . At 30, 45, and 60 days post differentiation, green fluorescence was imaged with an Evolve 512 Delta camera at ≥190 frames per second, and the relative change in fluorescence signal was measured. The time from upstroke to 80% repolarization (APD 80 ) was used to index the APD while the magnitude of peak transient, time to peak, and decay time constant were used as metrics for calcium transients. All metrics were quantified using custom Matlab (Mathworks) scripts. For all experiments involving treatment with CRISPRi, control cells were recorded on the same day and were from the same culture, minimizing any culture-dependent variability of the cells.
Statistical Analysis
All parameters are shown as mean±SEM. Technical and biological replicates are indicated in the figure legend. The D'Agostino and Pearson omnibus normality test was used to confirm a normal distribution before application of the statistical test for comparison of means. Data that did not initially correspond to a normal distribution were logarithmically transformed. The F test was used to compare variances, and a 2-sided Student t test (adjusted for unequal variance where applicable) was used to compare the difference in means across sample groups. Reported P values are from the 2-sided Student t test. Minimal sample size to ensure adequate power was determined as previously described.
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Results
Proband Identification and Generation of MutationHarboring iPSCs
An increasing number of patients are being diagnosed with calmodulinopathies resulting from single heterozygous missense mutations within their CALM1, CALM2, or CALM3 genes. Here, we focus on a p.D130G-CaM mutation identified within CALM2 of a female infant with severe LQTS. 1 The proband was born at term and noted to have bradycardia ( Figure 1 ). An ECG, recorded 12 hours after birth, revealed a QTc of 740 ms and 2:1 atrioventricular block ( Figure 1A ). She was treated with β-blockers, phenytoin, spironolactone, potassium, and placement of a single-chamber pacemaker within the first week of life. At 6 years of age, a single-chamber implantable cardioverter-defibrillator was implanted, and β-blocker therapy was continued. At 11 and 14 years of age, she experienced appropriate defibrillator discharges for ventricular fibrillation.
Next-generation whole-exome sequencing followed by CALM1, CALM2, and CALM3 gene-specific analysis identified a p.D130G-CaM mutation (c.389 A>G, CALM2) within the patient ( Figure 1B ). The mutation maps to an EF-hand within CaM ( Figure 1C) , and similar to other calmodulinopathic mutations, causes a reduction in the Ca 2+ binding affinity. 2 To create a model system with which to understand the pathogenesis and treatment options for this type of CaMmediated LQTS, multiple clones of iPSCs were generated from the patient's skin biopsy. Two clones with normal karyotypes at passage 25 and expressing the pluripotency markers (Nanog, Oct4, and SSEA4) were selected (Online Figure I) . f r r r In addition, the ability to generate each of the 3 germ layers was confirmed by staining differentiated embryoid bodies for α-fetoprotein (endoderm), smooth muscle actin (mesoderm), and glial fibrillary acidic protein (ectoderm) and by analysis of teratoma formation (Online Figure II) . Monolayers of iPSCCMs (iPSC D130G-CaM -CMs) were then generated from these 2 clones of iPSCs.
To confirm that the background of these iPSC D130G-CaM -CMs was not significantly different from iPSCs derived from healthy individuals, we quantified the mRNA levels for multiple proteins that could potentially alter cardiac AP morphology and excitation-contraction coupling. Compared with WT iPSCCMs (iPSC WT -CMs), we found no difference in the mRNA levels of CALM1, CALM2, CALM3, CACNA1C, KCNH2, NCX1, SCN5A, PLN, or SERCA2 (Online Figure IV) . Only KCNQ1 and RYR2 seemed somewhat elevated in the iPSC D130G-CaM -CMs; however, this variation would not be expected to contribute to a LQT phenotype. Importantly, this validates our iPSC WT -CMs as a relevant control, despite the potential variability that can occur because of differing genetic backgrounds. 23 
Altered APs and Calcium Transients in iPSC D130G-CaM -CMs
Previous work has linked mutations in CaM with LQTS; however, direct evidence demonstrating AP prolongation because of the D130G-CaM mutation has yet to be shown in human cardiomyocytes. We, therefore, characterized the iPSC D130G-CaM -CMs to confirm that these cells exhibit prolonged APDs that typically underlie LQTS. To measure APDs, the monolayers were transduced with the genetically encoded voltage sensor ASAP1, which features rapid kinetics and stable longterm expression, allowing accurate APD measurements over multiple time points. 20 The resultant APDs ( Figure 1D and 1E) measured from WT iPSC-CMs (iPSC WT -CMs) were comparable to those previously reported (Online Table I ). 16, 24 Under these same conditions, iPSC D130G-CaM -CMs exhibited dramatically longer APs and APDs (Figure 1G and 1J ; red) compared with their WT counterparts (gray). This result could be observed at multiple pacing frequencies ( Figure 1H and 1K) , a feature associated with increased arrhythmogenic risk. 25 Moreover, the phenotype was stable for long periods of time Hz, recorded via fluorescence imaging using ASAP1. Scale bar indicates change in fluorescence as measured by ∆F/F 0 . E, Population data for mean AP durations (APDs) at various pacing cycle lengths (CL) for iPSC WT -CMs (n=9). Error bars indicate ±SEM throughout. Each biological replicate (n) is an average value of 2 technical replicates, here and throughout this figure. F, Population data for iPSC WT -CM APDs at a 2-second cycle length across multiple time points (n=9, 9, and 7 on days 30, 45, and 60, respectively). G, Exemplar APs from iPSC D130G-CaM -CMs (red). WT reproduced in gray. H, Average APD data for iPSC D130G-CaM -CMs (red; n=7). WT reproduced in gray (***P<0.001 compared with WT; corrected for unequal variance of normal distributions). I, Average APDs at a 2-s cycle length from D130G iPSCs are stable across time (n=7, 7, and 7 on days 30, 45, and 60, respectively). J-L, Alternate D130G clone demonstrating the same result as G-I (n=9; ***P<0.001 compared with WT and corrected for unequal variance of normal distributions).
in culture, such that APDs measured at 30 days in culture were not significantly different than those measured after 45 or 60 days ( Figure 1F , 1I, and 1L; Online Figure VI) .
In addition to the electrical disturbance, dysfunctions in Ca 2+ cycling are often associated with arrhythmogenesis in LQTS. 26 As such, we examined the intracellular Ca 2+ transients of iPSCCMs using GCaMP6f, a genetically encoded Ca 2+ sensor with a high signal-to-noise ratio and fast kinetics.
21 Figure 2A shows the calcium transients (CaTs) from a monolayer of iPSC WT -CMs paced at 0.25 Hz with the rise and decay kinetics comparable to those previously reported. 27 However, monolayers of iPSC D130G-CaM -CMs exhibit CaT amplitudes over 3 times larger than WT with slower rise and decay kinetics ( Figures 2B through 2F) , akin to the phenotype observed in CaM D130G -overexpressing rodent myocytes. 10, 11 Likewise, these CaT effects were stable over time (Online Figure VII) . Although sarcoplasmic reticulum content of the iPSC D130G-CaM -CMs was not significantly different from the WT myocytes (Online Figure VIII) , the trend was in the direction of increased sarcoplasmic reticulum Ca
2+
. Thus, the patient-derived iPSC D130G-CaM -CMs recapitulate the LQTS phenotype, demonstrating significant proarrhythmic potential despite limited, native expression levels of CaM D130G .
IPSC D130G-CaM -CMs Exhibit Diminished CDI
Previous studies have implicated the cardiac LTCC as a major contributor to the LQT phenotype in patients with CaM-mediated LQTS. 10, 11 In particular, the D130G mutation weakens the affinity of Ca 2+ binding to CaM, 2 resulting in a significant decrease in CDI when CaM D130G is overexpressed in rodent myocytes. 10, 11 However, the relevance of these results remains to be established in human CMs with physiological levels of mutant CaM expression. We, therefore, examined the effect of the D130G mutation on LTCC CDI in patient-derived iPSC-CMs. To this end, we performed whole-cell patch clamp recordings of individual CMs. IPSC WT -CMs exhibited a rapid decay in their Ca 2+ current in response to a 10-mV depolarizing step ( Figure 3A, red) . To isolate the extent of pure CDI, Ba 2+ , which binds poorly to CaM, was used as the charge carrier to gauge the extent of voltage-dependent inactivation within the same cell. 10 CDI can be seen as the excess inactivation of the Ca 2+ trace ( Figure 3A ; red) compared with the Ba 2+ trace (black). Population data showing the average normalized peak Ba 2+ currents as a function of voltage is shown in Figure 3B . For CDI quantification, we first measure the fraction of current remaining after 50 ms (r 50 ) for both the Ca 2+ and Ba
2+
currents. By plotting the r 50 values as a function of voltage, a hallmark U-shaped relationship is observed with Ca 2+ as the charge carrier ( Figure 3C, red) . The difference between the Ba 2+ and Ca 2+ r 50 values at 10 mV, normalized by the Ba 2+ r 50 value, quantifies the extent of pure CDI ( Figure 3C ). Applying this same protocol to the iPSC D130G-CaM -CMs reveals a profound attenuation in the kinetics and extent of CDI ( Figures 3D and  3G ) without altering the voltage activation profile ( Figures 3E  and 3H ). Quantifying this result across voltages ( Figures 3F  and 3I ) confirms a significant decrease in CDI (red; P<0.01), an effect that is maintained over time in culture (Online Figure  IX) . Importantly, this reduction of CDI is significant even in the iPSC D130G-CaM -CM background, where the patient's other 5 CALM alleles are WT. Thus, these iPSC D130G-CaM -CMs not only provide a viable model system for this LQTS-associated calmodulinopathy but also suggest that the loss of LTCC CDI is a significant underlying mechanism leading to arrhythmogenesis in these patients.
To further bolster this LTCC-centric hypothesis, we examined the effects of other potential CaM targets that might contribute to the LQT phenotype of calmodulinopathy patients. To date, only 3 genetic forms of LQTS result from mutations within a channel known to be modulated by CaM. LQT1 results from loss-of-function mutations in KCNQ1, LQT3 results from gain-of-function mutations in SCN5A, and LQT8 is caused by inactivation altering mutations within CACNA1C, somewhat mirroring the LTCC effects described in this study. Of these forms of LQT, only LQT8 approaches the extreme APD prolongation seen in calmodulinopathy patients. 28, 29 To corroborate this in our model system, we mimicked the effect of each LQT mechanism pharmacologically. Consistent with clinical findings, enhancement of the current through the LTCC had a profound effect on APD, whereas blocking I KS or enhancing Na V 1.5 produced more modest APD prolongation (Online Figure X) . We next used a validated model of an adult mammalian cardiomyocyte 8, [30] [31] [32] to investigate the fraction of channels harboring a CaM D130G required to produce electric instability via an LTCC CDI-specific mechanism in silico (Online Figure XI) . Indeed, only a small fraction of channels Figure 2 . Disruption of calcium handling in calmodulinopathy induced pluripotent stem cells (iPSCs). A, Exemplar calcium transients (CaTs) recorded from induced pluripotent stem cell-derived cardiomyocytes (iPSC WT -CMs; WT) using GCaMP6f. Scale bar indicates change in fluorescence as measured by ∆F/ F 0 . B, Exemplar CaTs recorded from iPSC D130G-CaM -CMs (red) compared with WT (gray). C, Exemplar CaTs from an alternate D130G clone. D-F, Population data demonstrating larger amplitude and slower kinetics for both iPSC D130G-CaM -CMs clones (red; peak, mean peak fluorescence change; T peak , mean time to peak; τ decay , mean decay time constant; ***P<0.001 compared with WT and corrected for unequal variance, all populations were normally distributed). Error bars indicate ±SEM throughout. Biological replicates (n) are 10, 7, and 7 for WT, D130G clone#1, and D130G clone#2, respectively. Each biological replicate (n) is an average value of 2 technical replicates.
harboring CaM D130G was necessary to achieve significant arrhythmogenesis in the model cells. Importantly, the simulation predicted a threshold for the induction of electric instability precisely matching the expected levels of mutant CaM expression in calmodulinopathy patients based on reported CALM gene expression. 33 Such a threshold highlights an important therapeutic principle; namely, only a small reduction in the expression levels of the mutant CaM may be needed to provide significant clinical benefit to patients.
Toward a New Therapeutic Strategy
Having confirmed a major role for LTCC CDI deficits in generating the LQT phenotype in this calmodulinopathy patient, we next considered the implications of this mechanism on a novel therapeutic intervention. As our results predict a significant functional benefit conferred by even a small shift in the expression of mutant versus WT CaM (Online Figure XI) , we sought to reduce the fraction of mutant CaM expressed in patients with CaM-mediated LQTS. Because all 3 CALM genes encode for identical CaM proteins, we reasoned that we might be able to take advantage of the sequence variation at the nucleotide level. We, thus, used CRISPRi [13] [14] [15] to decrease the transcription of the CALM2 alleles, both the WT and the D130G-containing CALM2 alleles.
The CRISPRi technology uses a short gRNA, which binds specifically to a target nucleotide sequence. By pairing this gRNA with a nuclease-dead Cas9 (dCas9) fused to suppressor KRAB, selective suppression of the target gene could be achieved. Our first step was, therefore, to optimize gRNA sequences capable of selectively targeting CALM2. Sequence optimization was first done in silico, 19 followed by evaluation of the efficiency and specificity of each candidate gRNA in HEK293 cells via quantitative real-time polymerase chain reaction (Online Figures XII and Table II) . We choose design 21 ( Figure 4A ) because this gRNA specifically reduced the expression of CALM2, without appreciable alteration of either CALM1 or CALM3.
Having identified a potential treatment strategy, we next sought to test this approach within our iPSC D130G-CaM -CMs. Monolayers were lentivirally transduced with genes encoding dCas9-mRuby-KRAB and gRNA-cyan fluorescence protein, and expression of both constructs was confirmed by visualization of red and blue fluorescence, respectively. Compared with untreated iPSC D130G-CaM -CMs, the CRISPRitreated iPSC D130G-CaM -CMs exhibited significantly lower levels of CALM2 mRNA with unaltered levels of CALM1 and CALM3 ( Figure 4B ) mRNA level with the overall reduction of total amount of CaM protein (Online Figure V) . In addition, we probed the effect of treatment on multiple cardiac genes and found no significant change in the mRNA levels of CACNA1C, KCNQ1, KCNH2, SCN5A, RYR2, SERCA2, NCX1, or PLN (Online Figure IV) . Having achieved a selective decrease in CALM2 transcription, we next tested whether this reduction correlated with a functional effect within the iPSC D130G-CaM -CMs. Indeed, treatment of the monolayers resulted in a substantial shortening of the APDs in response to 0.5-Hz stimulation ( Figure 4C , blue) compared with untreated monolayers (gray). This effect was consistent across multiple trials, resulting in a significant decrease in APD as compared with untreated iPSC D130G-CaM -CMs ( Figure 4C, right) , establishing CRISPRi as a robust and promising strategy for the treatment of CaM-mediated LQTS.
Having established functional rescue of the iPSC D130G-CaM -CM monolayers, we next considered the underlying mechanism. Our previous results suggest that APD prolongation of these cells stems from a CDI deficit of the LTCC (Figure 3) . We, therefore, predicted that successful treatment of these cells should correspond to a correction (increase) in the CDI of the LTCCs. Indeed, treated iPSC D130G-CaM -CMs displayed significantly faster CDI ( Figure 4D ) as compared with untreated cells. In fact, CDI in the treated cells was nearly identical to that of iPSC WT -CMs (Figure 3) . Thus, CRISPRi effectively reduced the expression of the mutant and WT CALM2 alleles, resulting in normalization of the APD and restoration of LTCC's CDI mechanism.
Generalization of the CRISPRi Strategy Across Calmodulinopathy Subtypes
Beyond the proband described in this study, the CRISPRi treatment strategy is readily generalizable to any calmodulinopathy. In contrast to the classic CRISPR/Cas9 genome-editing technique where the gRNA sequence is tailored to an exact locus within the affected gene, CRISPRi targets the entire gene of interest itself, resulting in repression regardless of the specific base-pair alteration. This technique can, therefore, be adjusted to target CALM1 or CALM3 genes, providing efficacy across calmodulinopathy patient populations agnostic to the phenotype. We, thus, created gRNA sequences targeting each of the CALM genes ( Figure 5A ; Online Figure XII and Table II) and tested their efficacy in iPSC-CMs. Using iPSC WT -CMs, we are indeed able to specifically decrease the expression of either CALM1 ( Figure 5B ) or CALM3 ( Figure 5C ), thus providing a modular toolkit for the treatment of calmodulinopathies resulting from a mutation within any of the 3 CALM genes.
Discussion
IPSC D130G-CaM -CMs provide a good model system for investigating the underlying pathology of LQTS-associated calmodulinopathies. Two distinct iPSC D130G-CaM -CM clones each formed a stable contracting syncytium and exhibited prolonged APs, Ca 2+ cycling disturbances, and diminished LTCC CDI across extended culture. Creation of this model system enabled the generation and testing of a new therapeutic strategy. Taking advantage of the genome targeting precision of CRISPRi, we were able to selectively and efficiently silence both the WT and the D130G-containing CALM2 alleles, resulting in functional rescue of both LTCC CDI and cardiac AP morphology. This proof-of-principle therapy thus represents a first step toward a novel, targeted therapeutic design for calmodulinopathies.
Previous studies on the underlying mechanism of LQTS-associated calmodulinopathies have involved the overexpression of mutant CaM in rodent myocytes. 10, 11 Although such studies have implicated the LTCC 10 and ruled out the Na V 1.5 channel 11 as major contributors to the LQT phenotype of calmodulinopathy patients, they do not represent the native expression levels of mutant CaM. In particular, calmodulinopathy patients harbor a single heterozygous mutation in only 1 of 3 redundant CALM genes. The ability of the resultant small fraction of mutant CaM protein to produce the severe phenotype seen in patients has been attributed to CaM preassociation to the LTCC. 10 In this context, a fraction of LTCCs prebound to mutant CaM will display diminished CDI, disrupting the precise tuning of the AP by Ca 2+ influx. The profound prolongation of the APs and decreased CDI observed in the iPSC D130G-CaM -CMs corroborate just such a dominant negative effect. Moreover, the amelioration of the LQTS phenotype of the iPSC D130G-CaM -CMs via suppression of CALM2 transcription firmly establishes this mutation as the causative genetic mechanism. However, this new mechanistic insight also presents a significant challenge to the treatment of these calmodulinopathy patients. The preassociation of LTCCs with both mutant and WT CaM makes selective targeting of the disrupted LTCCs nearly impossible. Thus, any treatment option for these patients must selectively target the mutant CaM before cytosolic expression and binding to the LTCC.
Fortunately, CRISPRi provides just such a therapeutic option. In fact, recent work demonstrates that CRISPRi is capable of robust gene knock down within both iPSCs and iPSC-derived cardiomyocytes, making this a highly attractive method that has already been validated for our model system. Moreover, this technique offers the advantages of selectivity, reversibility, and generalizability. [13] [14] [15] That is, RNA transcription of specific mutation-containing CALM genes can be repressed, without modifying the patient genome and risking permanent alteration of off-target or downstream elements. 13, 14 Furthermore, this technique is generalizable to any calmodulinopathy. Here, we present a simple therapeutic toolbox in which 3 gRNAs targeting CALM1, CALM2, or CALM3 can be chosen to match any calmodulinopathy patient. Importantly, this means that although this study focused on the LQTSassociated calmodulinopathies, the therapy developed here should also be effective for the catecholaminergic polymorphic ventricular tachycardia-and idiopathic ventricular fibrillation-associated calmodulinopathies. Moreover, as expected, because of the widespread distribution of CaM, calmodulinopathy patients also exhibit extracardiac phenotypes including seizures and developmental delays. 2 Importantly, the CRISPRi toolkit should be effective on these noncardiac symptoms, as targeting of the CRISPRi can be adjusted to include any affected organ systems. More broadly, this therapeutic principle could be applied to the treatment of any disease in which there is a redundancy of the affected gene. Thus, the CRISPRi strategy described here not only represents a promising new treatment option for calmodulinopathy patients but could also provide a generalizable strategy in the treatment of a variety of diseases. Fortuitously, development of CRISPR/Cas9 delivery into patients is already well underway, 34 propelling the translation of these findings toward improving patients' health and quality of life and in the case of patients with a LQTS-or catecholaminergic polymorphic ventricular tachycardia-or idiopathic ventricular fibrillation-associated calmodulinopathy, preventing sudden death in the young.
